Document Detail

Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease.
MedLine Citation:
PMID:  18525128     Owner:  NLM     Status:  MEDLINE    
The search for molecular biomarkers for diagnosing and classifying dementias is becoming a high priority need. Neurosin (Kallikrein 6, hk6) is one molecule with promising preliminary results since its levels in brain tissue, cerebrospinal fluid and blood have been found to be abnormal in Alzheimer's disease (AD). In this study, we measured plasmatic levels of neurosin in healthy individuals and patients with cognitive symptoms independently of what the final diagnosis was. We collected plasma samples from 228 controls and 447 patients finally diagnosed with either AD, Mild Cognitive Impairment, Dementia with Lewy Bodies or Parkinson-Dementia, Frontotemporal Dementia, Huntington's disease, Primary Progressive Aphasia, Corticobasal degeneration, Creutzfeldt-Jakob's disease or Pseudodementia. We found that plasmatic levels of neurosin increase with age in healthy individuals and decrease in patients with AD. Plasmatic levels of neurosin differ significantly between AD and Vascular Dementia, Pseudodementia and the control group. Analyses comparing any other form of neurodegenerative dementia to the AD group did not show significant differences. In conclusion, measurement of plasmatic levels of neurosin is useful to distinguish AD patients from subjects without neurodegenerative dementia (either Pseudodementia, Vascular Dementia or controls) although it is not useful to distinguish among neurodegenerative dementias.
Manuel Menendez-Gonzalez; Patricia Castro-Santos; Ana Suarez; María Teresa Calatayud; Pablo Perez-Pinera; Marta Martinez; Renee Ribacoba; Carmen Gutierrez
Related Documents :
20205668 - Alzheimer's disease (ad) and mild cognitive impairment (mci) patients are characterized...
8845698 - Quantified electroencephalographic correlates of relative frontal or parietal hypoperfu...
19021838 - Subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral ...
20157248 - Multi-center study on alzheimer's disease using fdg pet: group and individual analyses.
8933318 - Sudden respiratory deterioration in the positive pressure ventilated patient: an organi...
11700398 - Glutamine administration reduces gram-negative bacteremia in severely burned patients: ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of Alzheimer's disease : JAD     Volume:  14     ISSN:  1387-2877     ISO Abbreviation:  J. Alzheimers Dis.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-06-05     Completed Date:  2008-08-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9814863     Medline TA:  J Alzheimers Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  59-67     Citation Subset:  IM    
Department of Internal Medicine, Hospital Alvarez-Buylla, Mieres, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Alzheimer Disease / blood,  diagnosis*
Biological Markers / blood
Cognition Disorders / blood,  diagnosis
Dementia / blood,  diagnosis
Diagnosis, Differential
Enzyme-Linked Immunosorbent Assay
Kallikreins / blood*
Middle Aged
Neurodegenerative Diseases / blood,  diagnosis
Predictive Value of Tests
Reg. No./Substance:
0/Biological Markers; EC 3.4.21.-/KLK6 protein, human; EC 3.4.21.-/Kallikreins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy.
Next Document:  Involvement of ApoE E4 and H63D in sporadic Alzheimer's disease in a folate-supplemented Ontario pop...